A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes
Status:
Completed
Trial end date:
2019-12-14
Target enrollment:
Participant gender:
Summary
This study is investigating the safety and tolerability of the new medicine NNC0268-0965
(referred to as insulin 965), its concentrations in the blood and its effect on blood sugar
for the treatment of diabetes. This first part of the study is conducted in healthy people,
while there is a second part involving people with type 1 diabetes. The study will test how
insulin 965 is tolerated by the participants' body, how it is taken up in the participants'
blood, how long it stays there and how blood sugar is lowered. Participants will either get
the new insulin 965 or placebo (an injection that does not contain active medicine) - which
treatment you get is decided by chance. It is the first time that insulin 965 is tested in
humans. Participants will get one injection of either insulin 965 or placebo under the skin
of the left thigh. The study will last for about 5 weeks. Participants will have 6 clinic
visits with the study doctor. People cannot be in the study if the study doctor thinks that
there are risks for their health.